Clinical Trial Update: JAK Inhibitor Dose TAPering Strategy Study [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating a dose tapering strategy for a JAK inhibitor in rheumatoid arthritis, and the study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Rhumatoid Arthisis | Phase 4 | Status: NOT_YET_RECRUITING